DOP2021000185A - Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por vhb o enfermedades inducidas por vhb - Google Patents

Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por vhb o enfermedades inducidas por vhb

Info

Publication number
DOP2021000185A
DOP2021000185A DO2021000185A DO2021000185A DOP2021000185A DO P2021000185 A DOP2021000185 A DO P2021000185A DO 2021000185 A DO2021000185 A DO 2021000185A DO 2021000185 A DO2021000185 A DO 2021000185A DO P2021000185 A DOP2021000185 A DO P2021000185A
Authority
DO
Dominican Republic
Prior art keywords
hbv
treatment
fused ring
induced diseases
pyrimidone derivatives
Prior art date
Application number
DO2021000185A
Other languages
English (en)
Inventor
Céline Grosse Sandrine
Martin Berke Jan
Jacoby Edgar
HSIAO Meng-Yang
Hugo Maria Jonckers Tim
Rudolf Romanie Kesteleyn Bart
Julien Last Stefaan
Martinez Lamenca Carolina
Perrier Mathieu
Maria Aloysius Pieters Serge
Jean-Marie Bernard Raboisson Pierre
Tahri Abdellah
Vandyck Koen
Gaston Verschueren Wim
Hu Lili
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of DOP2021000185A publication Critical patent/DOP2021000185A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente solicitud se refiere a compuestos de acuerdo con la fórmula (I), composiciones farmacéuticas que comprenden al menos uno de dichos compuestos, su uso como medicamento y su uso en el tratamiento de la infección crónica por el virus de la hepatitis B (VHB). La divulgación se refiere además a métodos para preparar compuestos de acuerdo con la fórmula (I).
DO2021000185A 2019-03-14 2021-09-09 Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por vhb o enfermedades inducidas por vhb DOP2021000185A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19162954 2019-03-14
PCT/EP2020/056884 WO2020182990A1 (en) 2019-03-14 2020-03-13 Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases

Publications (1)

Publication Number Publication Date
DOP2021000185A true DOP2021000185A (es) 2022-01-16

Family

ID=65817822

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2021000185A DOP2021000185A (es) 2019-03-14 2021-09-09 Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por vhb o enfermedades inducidas por vhb

Country Status (23)

Country Link
US (1) US20230091047A1 (es)
EP (1) EP3938362A1 (es)
JP (1) JP2022524456A (es)
KR (1) KR20210139319A (es)
CN (1) CN113710667A (es)
AR (1) AR118358A1 (es)
AU (1) AU2020235270A1 (es)
BR (1) BR112021017415A2 (es)
CA (1) CA3132531A1 (es)
CL (1) CL2021002390A1 (es)
CO (1) CO2021011295A2 (es)
CR (1) CR20210482A (es)
DO (1) DOP2021000185A (es)
EA (1) EA202192512A1 (es)
EC (1) ECSP21067189A (es)
IL (1) IL286210A (es)
JO (1) JOP20210249A1 (es)
MA (1) MA55286A (es)
MX (1) MX2021011107A (es)
PE (1) PE20212325A1 (es)
SG (1) SG11202109575UA (es)
TW (1) TW202100524A (es)
WO (1) WO2020182990A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202227435A (zh) * 2020-09-11 2022-07-16 愛爾蘭商健生科學愛爾蘭無限公司 用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之稠合環嘧啶酮衍生物
CN116724038A (zh) * 2020-10-21 2023-09-08 安力高医药股份有限公司 双环化合物
WO2022266193A1 (en) * 2021-06-18 2022-12-22 Aligos Therapeutics, Inc. Bicyclic compounds
US20230374008A1 (en) * 2022-04-20 2023-11-23 Aligos Therapeutics, Inc. Bicyclic compounds
WO2023205653A1 (en) * 2022-04-20 2023-10-26 Aligos Therapeutics, Inc. Bicyclic compounds
WO2024015425A1 (en) 2022-07-14 2024-01-18 Fmc Corporation Herbicidal benzoxazines
US20240150351A1 (en) * 2022-09-30 2024-05-09 Aligos Therapeutics, Inc. Bicyclic compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2078719A4 (en) 2006-09-28 2009-11-11 Dainippon Sumitomo Pharma Co COMPOUND WITH BICYCLIC PYRIMIDINE STRUCTURE AND THE COMPOUND CONTAINING PHARMACEUTICAL COMPOSITION
JP2010524940A (ja) * 2007-04-20 2010-07-22 シェーリング コーポレイション ピリミジノン誘導体およびそれらの使用方法
CN101854597B (zh) 2009-04-03 2015-06-03 中兴通讯股份有限公司 大消息模式融合ip消息传输方法及系统
WO2011111880A1 (ko) * 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
JP2012126698A (ja) * 2010-12-17 2012-07-05 Tsutomu Takeuchi テトラヒドロピリドピリミジン誘導体を有効成分とするｂａｆｆの結合阻害剤
JP6713465B2 (ja) * 2014-12-30 2020-06-24 ノヴィラ・セラピューティクス・インコーポレイテッド Ｂ型肝炎感染症治療のための誘導体及び方法
CN110088104B (zh) * 2016-11-03 2022-04-12 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的四氢吡啶并嘧啶化合物

Also Published As

Publication number Publication date
CL2021002390A1 (es) 2022-04-22
EP3938362A1 (en) 2022-01-19
SG11202109575UA (en) 2021-09-29
CN113710667A (zh) 2021-11-26
AU2020235270A1 (en) 2021-08-12
ECSP21067189A (es) 2021-11-18
JP2022524456A (ja) 2022-05-02
IL286210A (en) 2021-10-31
CR20210482A (es) 2021-11-09
JOP20210249A1 (ar) 2023-01-30
CA3132531A1 (en) 2020-09-17
MA55286A (fr) 2022-01-19
PE20212325A1 (es) 2021-12-14
AR118358A1 (es) 2021-09-29
US20230091047A1 (en) 2023-03-23
BR112021017415A2 (pt) 2022-02-01
TW202100524A (zh) 2021-01-01
KR20210139319A (ko) 2021-11-22
WO2020182990A1 (en) 2020-09-17
CO2021011295A2 (es) 2021-09-20
EA202192512A1 (ru) 2022-02-16
MX2021011107A (es) 2022-01-19

Similar Documents

Publication Publication Date Title
ECSP21067189A (es) Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por vhb o enfermedades inducidas por vhb
BR112018075465A2 (pt) agentes antivirais de hepatite b
CL2018002528A1 (es) Agentes anti virales de la hepatitis b.
EA201891876A1 (ru) Тетрациклические пиридоновые соединения в качестве противовирусных средств
UY38483A (es) Heterociclos funcionalizados como agentes antivirales
UY37741A (es) Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue
BR112017011941A2 (pt) compostos 5-amino-6h-tiazol [4,5-d] pirimidina-2,7-diona substituídos 3 para o tratamento e profilaxia de infecção viral
CL2015003370A1 (es) Derivados de sulfamoilpirrolamiday su uso como medicamentos para el tratamiento de la hepatitis b
BR112015024552A2 (pt) compostos de fórmula (a), composição farmacêutica, métodos para a preparação do composto e métodos de tratamento ou prevenção de infecções
CO2019010295A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
BR112017020837A2 (pt) compostos de carbamoilpiridona policíclicos e seu uso farmacêutico
CR20190504A (es) COMPUESTO DE AMIDA (Divisional 2015-0454)
DOP2011000343A (es) Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral
CO2019010292A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112015016325A2 (pt) Composto, composição farmacêutica, e, usos de uma composição, composto, pró-droga ou sal farmaceuticamente aceitável do mesmo
CO2019012035A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY38383A (es) Heterociclos funcionalizados como agentes antivirales
BR112014019584A8 (pt) Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
BR112017003242A2 (pt) composto, métodos para tratar infecção por vírus e para fabricação de um medicamento, composição farmacêutica, e, uso de um composto.
BR112019005205A2 (pt) composto de di-hidropirimidina e método de preparação e uso do mesmo
BR112021022889A2 (pt) Derivados heterocíclicos fundidos
BR112014015582A2 (pt) compostos antivirais
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?